Known targets — ChEMBL curated mechanism
FGFR3FLT1FLT3FLT4KDRKITPDGFRAPDGFRB
The experimentally established mechanism targets of Dovitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB known ✓ | P09619 | 16/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 16/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 1.00 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 18/20 | 1.00 |
| ▸ | LCK | P06239 | 3/20 | 1.00 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | RIOK3 | O14730 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | CHUK | O15111 | 1/20 | 1.00 |
| ▸ | MUSK | O15146 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dovitinib SCHEMBL29424010 | 1.00 | FGFR1 (1.00) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL29352967 | 1.00 | FGFR1 (1.00) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL248083 | 0.99 | FGFR1 (0.98) | FGFR1PDGFRBKDRFLT1LCK | |
| SCHEMBL14796707 | 0.96 | FGFR1 (0.93) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL30567813 | 0.93 | FGFR1 (0.86) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL949705 | 0.93 | FGFR1 (0.86) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL29352167 | 0.93 | FGFR1 (0.86) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL253137 | 0.93 | FGFR1 (0.86) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL29358063 | 0.93 | FGFR1 (0.86) | FGFR1PDGFRBKDRFLT1LCK | |
| Dovitinib SCHEMBL29351344 | 0.92 | FGFR1 (0.84) | FGFR1PDGFRBKDRFLT1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 730 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | claimed |
| WO-2021150792-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | MICURX PHARMACEUTICALS, INC. (US) | 2021-07-29 | — | — | WO | claimed |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2021-06-03 | — | — | US | claimed |
| EP-3773725-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | Loxo Oncology Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| US-20210023086-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | LOXO ONCOLOGY, INC. | 2021-01-28 | — | — | US | claimed |
| CN-106943355-B | Pharmaceutical composition | 诺华股份有限公司 | 2020-09-01 | — | — | CN | claimed |
| US-10724102-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2020-07-28 | — | — | US | claimed |
| US-20200163877-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2020-05-28 | — | — | US | claimed |
| US-20190321467-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2019-10-24 | — | — | US | claimed |
| WO-2019191659-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | LOXO ONCOLOGY, INC. (US) | 2019-10-03 | — | — | WO | claimed |
| WO-2011128405-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-10-20 | — | — | WO | claimed |
| EP-2364699-A1 | Joint use of sulfonamide based compound with angiogenesis inhibitor | Eisai R&D Management Co., Ltd. (JP) | 2011-09-14 | — | — | EP | claimed |
| US-20100105031-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | ESAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | claimed |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | claimed |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-16 | — | — | US | claimed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | CHIRON CORPORATION | 2005-09-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | PDGFRB 11/4885KDR 2/4885FLT1 3/4885 |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | PDGFRB 652/4885KDR 661/4885FLT1 1503/4885 |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | VEGFA, FLT4, MKI67 | PDGFRB 51/4885KDR 6/4885FLT1 5/4885 |
| US-20210023086-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | TP53, NCOA3, NCOA1 | PDGFRB 170/4885KDR 297/4885FLT1 962/4885 |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | PDGFRB 1041/4885KDR 277/4885FLT1 326/4885 |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | PDGFRB 4330/4885KDR 4369/4885FLT1 4681/4885 |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | KDR, FLT4, FLT1 | PDGFRB 162/4885KDR 1/4885FLT1 3/4885 |
| US-10724102-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | PDGFRB 652/4885KDR 661/4885FLT1 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.